| __timestamp | Axsome Therapeutics, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 381287000 |
| Thursday, January 1, 2015 | 2419289 | 452612000 |
| Friday, January 1, 2016 | 6343648 | 316800000 |
| Sunday, January 1, 2017 | 7206691 | 330100000 |
| Monday, January 1, 2018 | 9351522 | 265800000 |
| Tuesday, January 1, 2019 | 13598030 | 336200000 |
| Wednesday, January 1, 2020 | 28896749 | 423900000 |
| Friday, January 1, 2021 | 66646205 | 467000000 |
| Saturday, January 1, 2022 | 159253661 | 487000000 |
| Sunday, January 1, 2023 | 323123000 | 477100000 |
| Monday, January 1, 2024 | 411359000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, effective cost management is crucial. Over the past decade, United Therapeutics Corporation and Axsome Therapeutics, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, United Therapeutics maintained a relatively stable SG&A expense, peaking at approximately 487 million in 2022, reflecting a strategic focus on consistent operational efficiency. In contrast, Axsome Therapeutics experienced a dramatic increase, with expenses skyrocketing from a modest 1.4 million in 2014 to over 323 million by 2023, marking a staggering growth of over 23,000%. This surge highlights Axsome's aggressive expansion and investment in growth initiatives. As these companies continue to evolve, their SG&A trends offer valuable insights into their strategic priorities and market positioning.
Selling, General, and Administrative Costs: Pfizer Inc. vs Axsome Therapeutics, Inc.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared